Author Relationships With Industry and Other Entities (Relevant)—2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease (March 2014).

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/Partnership/Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness	Voting Recusals by Section*
Marie D. Gerhard-Herman, Chair	Harvard Medical School—Associate Professor	None	None	None	None	None	None	None
Heather L. Gornik, Vice Chair	Cleveland Clinic Foundation, Cardiovascular Medicine—Medical Director, Noninvasive Vascular Laboratory	None	None	Summit Doppler Systems Zin Medical	AstraZeneca Theravasc	None	None	3.1, 3.2, 5.1–5.3, and 5.6.
Coletta Barrett	Our Lady of the Lake Regional Medical Center—Vice President	None	None	None	None	None	None	None
Neal R. Barshes	Baylor College of Medicine, Division of Vascular Surgery and Endovascular Therapy Michael E. DeBakey Department of Surgery— Assistant Professor	None	None	None	None	None	None	None
Matthew A. Corriere	University of Michigan— Frankel Professor of Cardiovascular Surgery, Associate Professor of Surgery	None	None	None	None	None	None	None
Douglas E. Drachman	Massachusetts General Hospital—Training Director	Abbott Vascular St. Jude Medical	None	None	Atrium Medical Bard Lutonix	None	None	4, 8.1.1– 9.1.2, and 10.2.2.
Lee A. Fleisher	University of Pennsylvania Health System Department of Anesthesiology and Critical Care—Chair	None	None	None	None	None	None	None
Francis Gerry R. Fowkes	University of Edinburgh— Emeritus Professor of Epidemiology	AstraZeneca† Bayer Merck	None	None	None	None	None	5.1–5.3, 5.6, 5.10, 7, and 9.2.
Naomi M. Hamburg	Boston University School of Medicine, Cardiovascular Medicine Section—Associate Professor of Medicine	None	None	None	None	None	None	None
Scott Kinlay	VA Boston Healthcare System—Associate Chief, Cardiology Director, Cardiac Catheterization Laboratory & Vascular Medicine	None	None	None	Medtronic† The Medicines Company†	None	None	4, 5.6, 8.1.1, 9.1.1, 10.2.1 and 10.2.2.
Robert Lookstein	Mount Sinai Medical Center—Chief, Interventional Radiology; Professor of Radiology and Surgery; Vice Chair, Department of Radiology	Boston Scientific Medrad Interventional Possis The Medicines Company	None	Cordis‡	Shockwave (DSMB)	None	None	4, 5.6, 8.1.1, 9.1.1, 10.2.1 and 10.2.2.
Sanjay Misra	Mayo Clinic, Division of Vascular and Interventional Radiology—Professor; Department of Radiology—Interventional Radiologist	None	None	None	Johnson & Johnson (DSMB)	None	None	4, 7, 8, and 10.2.2.
Leila Mureebe	Duke University Medical Center—Associate Professor of Surgery, Division of Vascular Surgery	None	None	None	None	None	None	None
Jeffrey W. Olin	Ichan School of Medicine at Mount Sinai, Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health— Professor of Medicine, Cardiology; Director, Vascular Medicine	AstraZeneca Merck Novartis Plurestem	None	Northwind†	AstraZeneca†	None	None	5.1–5.3, 5.6, 5.10, and 12.
Rajan A. G. Patel	John Ochsner Heart & Vascular Center, Ochsner Clinical School, University of Queensland School of Medicine—Senior Lecturer	None	None	None	None	None	None	None
Judith G. Regensteiner	University of Colorado, Health Sciences Center, Division of Cardiology— Associate Professor of Medicine	None	None	None	None	None	None	None
Andres Schanzer	University of Massachusetts Medical School—Professor of Surgery and Quantitative Health Sciences; Program Director, Vascular Surgery Residency	Cook Medical	None	None	None	None	None	4, 8.1.1, 9.1.1 and 10.2.2.
Mehdi H. Shishehbor	Cleveland Clinic, Interventional Cardiology and Vascular Medicine— Director, Endovascular Services	BostonScientific‡ Medtronic‡	None	None	None	AtriumMedical AstraZeneca†	None	4, 8.1.1– 9.1.2, and 10.2.2.
Kerry J. Stewart	Johns Hopkins University, School of Medicine; Johns Hopkins Bayview Medical Center— Professor of Medicine; Director, Clinical and Research Exercise Physiology	None	None	None	None	None	None	None
Diane Treat-Jacobson	University of Minnesota, School of Nursing— Professor	None	None	None	None	None	None	None
M. Eileen Walsh	University of Toledo, College of Nursing— Professor	None	None	None	None	None	None	None

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

^*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Section numbers pertain to those in the full-text guideline.

^†Significant relationship.

^‡No financial benefit.

AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; ACC, American College of Cardiology; ACE, Accreditation for Cardiovascular Excellence; AHA, American Heart Association; AMA, American Medical Association; DSMB, data and safety monitoring board; EUCLID, Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease; FDA, US Food and Drug Administration; HRS, Heart Rhythm Society; MI, myocardial infarction; NCDR, National Cardiovascular Data Registry; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; PCORI, Patient-Centered Outcomes Research Institute; PI, primary investigator; PLX-PAD, placental-derived adherent stromal cell; SCAI, Society for Cardiovascular Angiography and Interventions; SCVS, Society for Clinical Vascular Surgery; SIR, Society of Interventional Radiology; SVM, Society for Vascular Medicine; SVN, Society for Vascular Nursing; SVS, Society for Vascular Surgery; TASC, Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease; VA, Veterans Affairs; VESS, Vascular and Endovascular Surgery Society; and VIVA, Vascular Intervention Advances.